NovoCure Limited — Company profile
Healthcare · Medical Devices · Switzerland
Last price 13.11 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 1.53B
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Company profile
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, France, Japan, Greater China, and internationally. Its TTFields devices include Optune Gio, Optune Lua, and Optune Pax. The company also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Baar, Switzerland.
Details
| Name | NovoCure Limited |
| Sector | Healthcare |
| Industry | Medical Devices |
| Employees | 1605 |
| Founded | 2000 |
| Ipo Date | 2015-10-02 |
| Ceo | Frank Leonard |
| Country | Switzerland |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| Isin | JE00BYSS4X48 |
| Cusip | G6674U108 |
| Cik | 0001645113 |
| Sic | 3841 |
Key executives
| Name | Title |
|---|---|
| Frank Leonard | Chief Executive Officer and Director |
| William F. Doyle | Executive Chairman |
| Christoph Brackmann | Chief Financial Officer |
| Michael Puri | Chief Human Resources Officer |
| Dr. Uri Weinberg M.D., Ph.D. | Chief Innovation Officer and Chief Medical Officer |
| Mukund Paravasthu | Chief Operating Officer |
| Adam Daney | Head of Investor Relations |
| Barak Ben-Arye | General Counsel |
Contact
| Address | Neuhofstrasse 21, Baar, 6340, Switzerland |
| Website | https://www.novocure.com |